-to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon-α-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45:1107-1110 betes at the time of clinical onset and 34 healthy control subjects (age: median 31 years; range 21-65 years, male/female ratio: 14/20) (Table 1) . IP-10/CXCL10 serum concentrations were not influenced by age at clinical diagnosis of Type 1 diabetes. Of interest, IP-10/CXCL10 serum concentrations were higher in Type 1 diabetic females (median 89.9 pg/ml; range 29.3-811.0 pg/ml) than in both healthy control females (median 68 pg/ml; range 41.0-186.0 pg/ml) (non-parametric MannWhitney test, p=0.01) and Type 1 diabetic males (median 57.4 pg/ml, range 12.8-1169.0 pg/ml) (non-parametric MannWhitney test: p=0.04) ( Table 1) . No statistically significant difference was observed between Type 1 diabetic and healthy male subjects.
. Serum concentrations of IP-10/CXCL10 in newlydiagnosed Type 1 diabetic patients and healthy control subjects 
To the Editor:
We read with interest the recent paper by Nicoletti et al. [1] reporting increased serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 in patients newly diagnosed with Type 1 diabetes mellitus. The results of this study, carried out in Caucasian subjects, are seemingly in line with those of a previous study in the Japanese population [2] . Furthermore, the finding of increased serum IP-10/CXCL10 concentrations in patients at high risk for developing the disease, especially if confirmed in larger prospective trials, seems of great pathogenetic and clinical relevance. In our previous experience, evaluating the potential role of the increased expression of the CXC chemokines and of IP-10/ CXCL10 in particular, in several endocrinological autoimmune conditions, comparable serum concentrations of IP-10/ CXCL10 were found between healthy control subjects and patients affected with Type 1 diabetes [3] . Furthermore, the few patients showing increased IP-10/CXCL10 serum concentrations were all positive for circulating ICA, while no information regarding the onset of disease was available [3] . According to the observations of Nicoletti et al., we have selected 70 Type 1 diabetic patients (age at the time of diagnosis: median 22 years, range 1-54 years, male/female ratio: 41/29) with newly diagnosed Type 1 diabetes. All patients had been identified by a regional Type 1 diabetes mellitus registry active in Umbria, a region of central Italy [4] . Serum samples were collected within 6 weeks from the initiation of insulin therapy and stored at −80°C until the IP-10/CXCL10 assay was carried out using a solid-phase ELISA from R & D Systems (Minneapolis, Minn., USA), a procedure identical to that described by Nicoletti et al. [1] .
Despite the enriched and more selected casistic, no statistically significant difference in IP-10/CXCL10 serum concentrations was registered between patients affected with Type 1 dia-
Observations
Quantitative traits associated with the Type 2 diabetes susceptibility allele in Kir6.2 studies have been conflicting: one investigation did not provide any evidence for an effect of the E23K variant on betacell function (n=298) [5] ; however, a recent larger study (n=519) has shown a reduction in beta-cell function in carriers of the K allele [7] . No assessment of E23K's effect on birth weight has been reported.
We used two large population based cohorts from the Barry-Caerphilly (BCG; n=645 adults) and Exeter Family (EFS; n=430 families) studies, to look for association between E23K genotype and beta-cell function and birth weight. The BCG and EFS cohorts have been described in detail elsewhere [8] . Briefly, BCG is a collection of subjects from Barry-Caerphilly in Wales, UK, studied from birth to young adulthood (average age at OGTT study 30 years). The EFS is an on going consecutive birth cohort of babies, fathers and 28-week pregnant mothers, from a geographically defined region of Exeter, UK (average adult age 30 years). All subjects were healthy UK Caucasians. Birth weight was corrected for sex and gestational age. In the BCG cohort, beta-cell function was assessed using OGTT data, by insulinogenic index (insulin 30 min-insulin 0 min / glucose 30 min-glucose 0 min) and AUC insulin, correcting for sex and current age.
The results from the two cohorts are shown in Table 1 . In the BCG OGTT, E23K genotype was not associated with a significant reduction in beta-cell function. Foetal growth, as measured by birth weight and birth length, was not associated with the E23K polymorphism in either cohort.
It is interesting that, despite strong evidence for a role in Type 2 diabetes, we have not found evidence that the E23K variant affects insulin secretion or alters birth weight; and this is the largest study yet reported. This would suggest the primary effect of E23K on diabetes susceptibility might be through beta-cell dysfunction not detectable in utero or in young adult life. Beta-cell dysfunction has been shown in one study [7] , and whilst this could represent stochastic variation for a weak association, there are two other possible reasons why our study and other previous studies have not shown association of E23K genotype with beta-cell function. Firstly, it could be that the use of normoglycaemic subjects limits the power of our study to detect association of diabetes-linked To the editor: K ATP channels are key to insulin secretion by the beta cell; they couple metabolism to plasma membrane depolarisation and, hence, insulin release. K ATP channels consist of two sub-units: Kir6.2 and SUR1, encoded by the genes KCNJ11 and ABCC8, respectively. Multiple large association studies have recently confirmed a Glu23Lys (E23K) polymorphism in KCNJ11 as a Type 2 diabetes susceptibility allele [1, 2] . The K allele confers a Type 2 diabetes odds ratio of about 1.2, and is carried by 58% of the population [1] . Functional studies have shown that K ATP channels encoded by the K allele have an increased open probability [3] .
Mutations in KCNJ11 that result in constant closure of the K ATP channels cause hyperinsulinaemia and, due to increased foetal insulin secretion, higher birth weight [4] . We therefore hypothesised that E23K, as a Type 2 diabetes susceptibility allele, would also affect the quantitative traits of beta-cell function and birth weight. Careful physiological studies, using hyperglycaemic clamps in small cohorts (n=75 and n=159), found no evidence of reduced insulin secretion in carriers of the E23K variant [5, 6] . However, Tschritter et al. did report association of the K allele with impaired glucagon suppression in response to hyperglycaemia [5] . The assessment of beta-cell function using the OGTT is less precise, but has allowed a larger number of subjects to be assessed. Results from such clinical or sub-clinical autoimmune diseases. This latter hypothesis would fit well with the finding of a sex-related increase of circulating IP-10/CXCL10 in patients affected with Type 1 diabetes. 
